TCRX — Pivotal Trial Launch of TSC-101
Jan 1, 2026, 4:59:59 AM UTC
Summary
TScan Therapeutics is set to launch a pivotal trial for TSC-101 aimed at treating residual disease and preventing relapse in patients with AML, ALL, and MDS later this year.
Company
TSCAN THERAPEUTICS INC (TCRX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.tscan.comSimilar Events
Expected Trial Completion for TSC-100 and TSC-101 in AML, ALL, and MDS
TScan Therapeutics is conducting a Phase 1 clinical trial evaluating TSC-100 and TSC-101, genetically engineered donor-derived T cells targeting HA-1 and HA-2, in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS) undergoing haploidentical donor transplantation. The study aims to assess safety, dose-limiting toxicities, and preliminary efficacy, with an expected completion date of June 1, 2026. TSC-100 and TSC-101 are investigational cell therapies designed to improve outcomes post-transplant by targeting minor histocompatibility antigens.
trial completionSafety and Response Data for Multiplex Therapy
TScan Therapeutics plans to share safety and response data for multiplex therapy in the second half of 2025.
clinical readoutPhase 2 Clinical Readouts
Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101.
clinical readoutLong Term Follow-up Study of TScan TCR-T Products
TScan Therapeutics, Inc. is set to complete a long-term follow-up study monitoring participants for safety and efficacy of its TCR-T products on September 1, 2040. This study will track participants for 15 years after they complete the TSCAN-001 interventional trial, with no additional study drug administered. The study aims to gather data on long-term outcomes in cancer treatment.
trial completion